ImmunoGen Quarterly Income Statements Chart
Quarterly
|
Annual
ImmunoGen Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-03-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2014-09-30 | 2013-12-31 | 2013-09-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2011-09-30 | 2010-12-31 | 2010-09-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2008-09-30 | 2007-12-31 | 2007-09-30 | 2007-06-30 | 2007-03-31 | 2006-12-31 | 2006-09-30 | 2006-06-30 | 2006-03-31 | 2005-12-31 | 2005-09-30 | 2005-03-31 | 2004-12-31 | 2004-09-30 | 2004-03-31 | 2003-12-31 | 2003-09-30 | 2003-03-31 | 2002-12-31 | 2002-09-30 | 2002-03-31 | 2001-12-31 | 2001-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| product revenue | 105,164,000 | 77,371,000 | 29,544,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| license and milestone fees | 30,780,000 | 7,382,000 | 6,973,000 | 30,892,000 | 19,564,000 | 2,677,000 | 252,000 | 157,000 | 62,417,000 | 97,000 | 945,000 | 283,000 | 29,551,000 | 79,000 | 5,079,000 | 79,000 | 1,747,000 | 672,000 | 1,321,000 | 11,540,000 | 60,739,000 | 18,730,000 | 76,000 | 76,000 | 10,077,000 | 10,692,000 | 6,070,000 | 6,234,000 | 25,678,000 | 13,167,000 | 22,010,000 | 429,000 | 933,000 | 1,187,000 | 866,000 | 1,810,000 | 1,266,000 | 827,000 | 1,831,000 | 2,223,000 | 2,680,000 | 4,188,000 | -6,323,415 | 1,497,000 | 3,428,000 | 1,406,000 | 1,340,000 | 3,275,000 | 1,275,000 | 1,261,000 | 3,039,394 | ||||||||||||||
| non-cash royalty revenue related to the sale of future royalties | 8,040,000 | 6,533,000 | 16,690,000 | 8,488,000 | 9,281,000 | 8,441,000 | 7,242,000 | 7,190,000 | 20,529,000 | 7,613,000 | 6,184,000 | 5,944,000 | 7,380,000 | 6,291,000 | 5,684,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development support | 855,000 | 455,000 | 109,000 | 73,000 | 758,000 | 388,000 | 6,000 | 4,000 | 11,000 | 5,000 | 5,000 | 7,000 | 51,000 | 17,000 | 218,000 | 388,000 | 388,000 | 383,000 | 2,004,000 | 1,478,000 | 1,354,000 | 1,335,000 | 1,059,000 | 848,000 | 772,000 | 776,000 | 1,922,000 | 1,990,000 | 2,257,000 | 2,036,000 | 1,377,000 | 1,068,000 | 2,005,000 | 1,495,000 | 1,805,000 | 1,283,000 | 782,000 | 3,207,000 | 3,672,000 | 4,473,000 | -18,657,514 | 6,583,000 | 6,593,000 | 5,507,000 | 5,674,000 | 5,258,000 | 5,231,000 | 5,645,000 | 4,572,792 | 4,065,955 | 4,089,008 | 4,059,524 | 3,886,386 | 1,207,681 | |||||||||||
| total revenues | 113,425,000 | 83,153,000 | 49,869,000 | 41,167,000 | 15,375,000 | 14,162,000 | 38,078,000 | 27,992,000 | 9,210,000 | 16,948,000 | 15,706,000 | 85,798,000 | 18,189,000 | 15,025,000 | 13,287,000 | 44,864,000 | 13,281,000 | 15,542,000 | 8,584,000 | 13,416,000 | 10,928,000 | 9,287,000 | 19,815,000 | 86,948,000 | 28,499,000 | 7,660,000 | 7,408,000 | 19,714,000 | 18,029,000 | 14,851,000 | 13,203,000 | 30,060,000 | 17,218,000 | 25,001,000 | 2,612,000 | 4,091,000 | 2,536,000 | 4,178,000 | 3,411,000 | 3,314,000 | 3,108,000 | 3,099,000 | 6,126,000 | 9,751,000 | 11,425,000 | -29,639,788 | 9,836,000 | 12,072,000 | 7,770,000 | 8,368,000 | 9,355,000 | 6,587,000 | 7,778,000 | 10,230,493 | 9,047,218 | 9,006,526 | 7,589,612 | 5,163,720 | 3,890,183 | 1,456,470 | 2,476,159 | 2,346,310 | 1,210,334 | 1,544,413 | 1,425,901 |
| cost and operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| research and development | 47,570,000 | 50,077,000 | 51,620,000 | 58,485,000 | 59,181,000 | 51,422,000 | 44,282,000 | 48,968,000 | 33,147,000 | 34,589,000 | 34,413,000 | 39,578,000 | 24,685,000 | 22,921,000 | 27,408,000 | 26,055,000 | 21,015,000 | 28,559,000 | 38,893,000 | 43,681,000 | 47,243,000 | 38,701,000 | 44,831,000 | 106,851,000 | 32,888,000 | 32,909,000 | 38,652,000 | 36,094,000 | 38,199,000 | 35,132,000 | 28,018,000 | 20,862,000 | 22,029,000 | 21,318,000 | 21,656,000 | 23,700,000 | 17,161,000 | 16,004,000 | 13,425,000 | 12,091,000 | 12,211,000 | 12,188,000 | 11,860,000 | 10,732,000 | 9,105,000 | -11,464,163 | 3,991,000 | 3,846,000 | 11,416,000 | 12,441,000 | 10,216,000 | 8,760,000 | 9,492,000 | 9,819,540 | 6,616,745 | 7,855,096 | 6,169,830 | 5,194,770 | 4,771,367 | 6,295,903 | 6,566,748 | 4,109,351 | 7,173,051 | 3,015,212 | 2,503,556 |
| selling, general and administrative | 37,744,000 | 36,356,000 | 40,016,000 | 42,065,000 | 33,623,000 | 23,793,000 | 16,648,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total cost and operating expenses | 87,469,000 | 87,342,000 | 92,262,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income from operations | 25,956,000 | -4,189,000 | -42,393,000 | -59,559,000 | -77,429,000 | -61,053,000 | -22,852,000 | -34,554,000 | -34,234,000 | -27,369,000 | -28,916,000 | 36,519,000 | -16,727,000 | -18,362,000 | -23,810,000 | 8,494,000 | -17,962,000 | -41,059,000 | -41,646,000 | -40,423,000 | -45,532,000 | -38,752,000 | -36,742,000 | -46,088,000 | -12,894,000 | -38,838,000 | 3,751,000 | -7,089,000 | -7,542,000 | -3,833,000 | -4,599,000 | -5,412,000 | |||||||||||||||||||||||||||||||||
| yoy | -133.52% | -93.14% | 85.51% | 72.36% | 126.18% | 123.07% | -20.97% | -194.62% | 104.66% | 49.05% | 21.44% | 329.94% | -6.88% | -55.28% | -42.83% | -121.01% | -60.55% | 5.95% | 13.35% | -12.29% | 253.13% | -0.22% | 30.99% | ||||||||||||||||||||||||||||||||||||||||||
| qoq | -719.62% | -90.12% | -28.82% | -23.08% | 26.82% | 167.17% | -33.87% | 0.93% | 25.08% | -5.35% | -179.18% | -318.32% | -8.90% | -22.88% | -380.32% | -147.29% | -56.25% | -1.41% | 3.03% | -11.22% | 17.50% | 5.47% | -20.28% | 257.44% | -66.80% | -6.01% | 96.76% | -16.66% | -15.02% | ||||||||||||||||||||||||||||||||||||
| operating margin % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest income | 7,383,000 | 5,223,000 | 624,250 | 757,000 | 874,000 | 865,000 | 923,000 | 875,000 | 758,000 | 718,000 | 544,655 | 457,176 | 363,947 | 321,739 | 353,305 | 379,372 | 592,466 | 740,814 | 892,407 | 1,084,386 | 1,295,868 | 1,644,937 | |||||||||||||||||||||||||||||||||||||||||||
| interest expense on term loan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| non-cash interest expense on liability related to the sale of future royalties and term loan | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| other income | -164,000 | -8,000 | 63,000 | 582,000 | -998,000 | -480,000 | -98,000 | -483,000 | -365,000 | 197,000 | -480,000 | 562,000 | 11,000 | 106,000 | -198,000 | 1,015,000 | -521,000 | 167,000 | -71,000 | -305,000 | -75,000 | -1,052,000 | 537,000 | 1,327,000 | 134,000 | 129,000 | -530,000 | 551,000 | 62,000 | 111,000 | 115,000 | 56,000 | 1,281,000 | 490,000 | 144,000 | 16,000 | 727,000 | 813,000 | 69,000 | -18,000 | -31,000 | -15,000 | 366,000 | 447 | 7,034 | 890 | 30,000 | 593 | 1,409,665 | 12,692 | 1,332 | 3,307 | 26,670 | ||||||||||||
| net income before income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax benefit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income | 30,748,000 | -41,014,000 | -40,980,250 | -77,755,000 | -62,021,000 | -24,145,000 | -37,172,000 | -37,339,000 | -30,741,000 | -34,051,000 | 31,388,000 | -22,374,000 | -24,298,000 | -29,088,000 | 4,814,000 | -21,750,000 | -43,446,000 | -43,751,000 | -41,799,000 | -46,807,000 | -41,624,000 | -38,613,000 | -78,667,000 | -17,345,000 | -44,731,000 | -45,922,000 | -31,928,000 | -33,227,000 | -33,740,000 | -22,282,000 | 3,813,000 | -11,226,000 | -1,351,000 | -24,393,000 | -25,192,000 | -19,483,000 | -14,233,000 | -12,888,000 | -12,124,000 | -13,008,000 | -12,375,000 | -9,397,000 | -6,212,000 | -1,032,000 | 14,439,013 | -5,161,000 | -3,044,000 | -6,253,000 | -6,645,000 | -2,981,000 | -3,502,000 | -4,706,000 | -3,550,976 | -2,209,378 | -2,470,506 | -759,921 | -1,332,609 | -4,126,414 | -4,616,581 | -5,285,198 | -3,221,537 | -6,872,868 | -1,732,252 | -1,592,523 | |
| yoy | -139.54% | 69.87% | 10.24% | 108.24% | 101.75% | -29.09% | -218.43% | 66.89% | 26.52% | 17.06% | 552.01% | 2.87% | -44.07% | -33.51% | -111.52% | -53.53% | 4.38% | 13.31% | -46.87% | 169.86% | -6.95% | -15.92% | 146.39% | -47.80% | 32.58% | 106.09% | -937.35% | 195.98% | 2397.41% | -8.65% | -115.14% | -42.38% | -90.51% | 89.27% | 107.79% | 49.78% | 15.01% | 37.15% | 95.17% | 1160.47% | -185.71% | 82.08% | 104.07% | -83.50% | -317.29% | 73.13% | -13.08% | 32.87% | 87.13% | 34.92% | 41.75% | 519.27% | 166.47% | -46.46% | -46.49% | -85.62% | -58.63% | -39.96% | 166.51% | 231.88% | |||||
| qoq | 0.08% | -47.30% | 25.37% | 156.87% | -35.05% | -0.45% | 21.46% | -9.72% | -208.48% | -240.29% | -7.92% | -16.47% | -704.24% | -122.13% | -49.94% | -0.70% | 4.67% | -10.70% | 12.45% | 7.80% | -50.92% | 353.54% | -61.22% | -2.59% | 43.83% | -3.91% | -1.52% | 51.42% | -684.37% | -133.97% | 730.94% | -94.46% | -3.17% | 29.30% | 36.89% | 10.44% | 6.30% | -6.80% | 5.12% | 31.69% | 51.27% | 501.94% | -107.15% | -379.77% | 69.55% | -51.32% | -5.90% | 122.91% | -14.88% | -25.58% | 32.53% | 60.72% | -10.57% | 225.10% | -42.97% | -67.71% | -10.62% | -12.65% | 64.06% | -53.13% | 296.76% | 8.77% | |||
| net income margin % | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share - basic | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income per common share - diluted | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding - basic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average common shares outstanding - diluted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | 7,000 | 9,000 | 9,000 | 10,000 | 1,000 | 6,000 | 10,000 | 4,949 | 19,628 | 2,872 | 4,207 | 10,290 | 10,290 | 12,850 | 22,275 | 33,000 | 33,000 | 61,812 | |||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share | -20 | -160 | -230 | -310 | -240 | -100 | -170 | -180 | -150 | -170 | 190 | -130 | -140 | -170 | 40 | -150 | -290 | -300 | -290 | -320 | -310 | -300 | -780 | -200 | -510 | -530 | -370 | -380 | -390 | -260 | 40 | -130 | -20 | -290 | -300 | -260 | -210 | -190 | -210 | -230 | -220 | -190 | -150 | -20 | 349.55 | -120 | -70 | -150 | -160 | -70 | -90 | -110 | -0.09 | -0.05 | -0.06 | -0.02 | -0.03 | -0.1 | -0.11 | -0.12 | -0.08 | ||||
| basic and diluted weighted-average common shares outstanding | 263,446,000 | 258,848,000 | 253,631,000 | 253,511,000 | 253,336,000 | 253,263,000 | 206,147,000 | 204,844,000 | 199,890,000 | 198,835,000 | 176,153,000 | 174,508,000 | 174,354,000 | 166,947,000 | 148,311,000 | 148,479,000 | 148,129,000 | 147,813,000 | 139,946,000 | 147,220,000 | 134,384,000 | 130,619,000 | 98,068,000 | 87,160,000 | 87,102,000 | 86,976,000 | 87,035,000 | 86,838,000 | 85,872,000 | 85,010,000 | 84,279,000 | 84,147,000 | 83,350,000 | 76,364,000 | 67,965,000 | 67,944,000 | 57,365,000 | 57,156,000 | 57,032,000 | 50,783,000 | 42,700,000 | 42,416,000 | 41,759 | 41,705,000 | 41,571,000 | 41,482,000 | 41,184,000 | 41,188,183,000 | 41,079,000 | 41,065,000 | 40,870,768 | 40,800,073 | 40,789,332 | 40,662,750 | 40,597,674 | 40,589,012 | 41,440,747 | 42,773,645 | 42,825,811 | ||||||
| investment income | 2,169,000 | 2,158,000 | 1,539,000 | 590,000 | 54,000 | 16,000 | 11,000 | 11,000 | 13,000 | 10,000 | 11,000 | 62,000 | 646,000 | 683,000 | 1,032,000 | 1,287,000 | 1,422,000 | 1,382,000 | 1,369,000 | 814,000 | 662,000 | 1,031,000 | 115,000 | 146,000 | 106,000 | 108,000 | 60,000 | 51,000 | |||||||||||||||||||||||||||||||||||||
| non-cash interest expense on liability related to the sale of future royalties | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total comprehensive loss | -41,014,000 | -59,008,000 | -77,755,000 | -62,021,000 | -24,145,000 | -37,172,000 | -37,339,000 | -30,741,000 | -34,051,000 | 31,388,000 | -22,374,000 | -24,298,000 | -29,088,000 | 4,814,000 | -21,750,000 | -43,446,000 | -43,751,000 | -41,799,000 | -46,807,000 | -41,624,000 | -38,613,000 | -78,667,000 | -17,345,000 | -44,731,000 | -45,922,000 | -31,928,000 | -33,740,000 | -22,282,000 | -11,226,000 | ||||||||||||||||||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total operating expenses | 57,237,250 | 92,804,000 | 75,215,000 | 60,930,000 | 62,546,000 | 43,444,000 | 44,317,000 | 44,622,000 | 49,279,000 | 34,916,000 | 33,387,000 | 37,097,000 | 36,370,000 | 31,243,000 | 56,601,000 | 50,230,000 | 53,839,000 | 56,460,000 | 48,039,000 | 56,557,000 | 133,036,000 | 41,393,000 | 46,498,000 | 47,950,000 | 47,329,000 | 46,253,000 | 43,461,000 | 35,113,000 | 26,309,000 | 28,555,000 | 26,313,000 | 27,120,000 | 29,339,000 | 22,002,000 | 19,692,000 | 16,789,000 | 15,538,000 | 16,097,000 | 15,780,000 | 15,538,000 | 16,685,000 | 13,258,000 | |||||||||||||||||||||||
| non-cash interest expense on liability related to the sale of future royalties and convertible senior notes | -3,432,000 | -2,428,000 | -2,546,000 | -2,611,000 | -3,046,000 | -10,107,000 | -3,575,000 | -5,018,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| interest expense on convertible senior notes | -24,000 | -25,000 | -23,000 | -23,000 | -24,000 | -1,915,000 | -1,125,000 | -1,150,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 13,578,000 | 10,297,000 | 9,728,000 | 10,209,000 | 9,738,000 | 10,231,000 | 9,767,000 | 8,864,000 | 9,803,000 | 9,208,000 | 8,700,000 | 10,778,000 | 9,752,000 | 8,347,000 | 8,652,000 | 9,995,000 | 25,792,000 | 8,119,000 | 9,459,000 | 9,298,000 | 11,235,000 | 8,054,000 | 8,329,000 | 7,095,000 | 5,447,000 | 6,526,000 | 4,995,000 | 5,464,000 | 5,639,000 | 4,841,000 | 3,688,000 | 3,364,000 | 3,447,000 | 3,886,000 | 3,592,000 | 3,678,000 | 3,527,000 | 2,424,000 | -8,199,971 | 2,848,000 | 2,566,000 | 2,797,000 | 2,579,000 | 2,193,000 | 2,332,000 | 2,794,000 | 2,161,167 | 2,033,973 | 1,493,002 | 1,768,550 | 1,412,206 | 1,834,223 | 1,502,253 | 1,296,974 | 1,742,374 | 1,576,469 | 1,242,262 | 1,198,575 | |||||||
| restructuring charges | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| restructuring charge | 559,000 | 406,000 | 870,000 | 686,000 | 1,731,000 | 393,000 | 386,000 | 4,130,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| clinical materials revenue | 2,170,000 | 1,427,000 | 336,000 | 702,000 | 3,676,000 | 678,000 | 46,000 | 53,000 | 1,198,000 | 3,000 | 2,325,000 | 2,027,000 | 125,000 | 8,000 | 734,000 | 147,000 | 1,781,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| non-cash debt conversion expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| royalty revenue | 195,000 | 4,166,000 | 2,335,000 | 2,053,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic weighted-average common shares outstanding | 86,970,000 | 85,431,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| dilutive impact of potential common shares | 1,845,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| diluted weighted-average common shares outstanding | 86,970,000 | 87,276,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total comprehensive income | -33,227,000 | 3,813,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| comprehensive loss | -1,351,000 | -24,393,000 | -25,192,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| clinical materials reimbursement | 281,000 | 1,307,000 | 106,000 | 243,000 | 998,000 | 486,000 | 696,000 | 3,399,000 | 2,764,000 | -4,658,859 | 1,756,000 | 2,051,000 | 857,000 | 1,354,000 | 822,000 | 81,000 | 831,000 | 2,415,158 | 3,637,099 | 2,865,583 | 936,405 | 226,827 | 1,948,700 | 492,458 | 947,896 | 826,269 | 601,777 | 840,855 | 934,561 | ||||||||||||||||||||||||||||||||||||
| income before benefit from income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | 1,000 | 5,000 | 12,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit for income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| benefit for income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cost of clinical materials reimbursed | 2,426,000 | 1,729,000 | -3,228,428 | 997,000 | 1,588,000 | 646,000 | 890,000 | 779,000 | 94,000 | 904,000 | 2,285,841 | 3,042,421 | 2,493,937 | 729,050 | 226,826 | 1,758,809 | 439,872 | 843,168 | 752,396 | 556,677 | 840,855 | 934,561 | |||||||||||||||||||||||||||||||||||||||||||
| expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| preclinical and clinical | 1,556,000 | 2,079,000 | 2,218,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| process and product development | 1,017,250 | 1,391,000 | 1,367,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| manufacturing | 3,336,500 | 4,504,000 | 4,337,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| total expenses | 11,648,000 | 15,810,000 | 15,922,000 | 14,859,000 | 15,910,000 | 13,188,000 | 11,186,000 | 13,190,000 | 14,266,548 | 11,693,139 | 11,842,035 | 8,667,430 | 6,833,802 | 8,364,399 | 8,238,028 | 8,706,890 | 6,604,121 | 9,306,197 | 5,098,329 | 4,636,692 | |||||||||||||||||||||||||||||||||||||||||||||
| net realized losses on investments | -1,000 | -8,250 | -7,000 | -22,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain on sale of assets | 250 | 1,000 | 1,000 | 1,000 | 2,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense | -6,243,000 | -6,645,000 | -2,980,000 | -3,496,000 | -4,696,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net realized gains on investments | 5,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| development fees | 41,000 | 203,149 | 310,325 | 509,763 | 43,179 | 87,476 | 178,306 | 48,578 | 40,370 | 148,616 | 314,742 | 94,723 | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| license fees and milestone payments | 1,033,839 | 1,542,172 | 2,550,504 | 1,050,507 | 646,326 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| revenue earned under collaboration agreements | 785,706 | 1,479,685 | 1,479,671 | 459,941 | 388,816 | 396,617 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| realized gains on investments | 162,846 | 217,569 | 153,450 | 170,277 | 555,289 | 8,473 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| net income before income tax expense | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| gain/(loss) on sale of assets | 200 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before income tax expense and cumulative effect of change in accounting principle | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| income before cumulative effect of change in accounting principle | -0.17 | -0.04 | -0.04 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| cumulative effect of change in accounting principle | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted net income per common share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| basic and diluted average common shares outstanding | 39,829,837 | 39,730,478 | 38,809,948 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| loss on the sale of assets |
We provide you with 20 years income statements for ImmunoGen stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ImmunoGen stock. Explore the full financial landscape of ImmunoGen stock with our expertly curated income statements.
The information provided in this report about ImmunoGen stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.